TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...

"Treatment with TREMFYA resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining," said ...

"For many patients, having a subcutaneous induction option is an important step forward—offering the flexibility of at-home administration after proper training without compromising efficacy," said ...

Johnson & Johnson (J&J) Innovation Medicine has submitted a request to the US Food and Drug Administration (FDA) to approve a new way of starting treatment with its drug Tremfya (guselkumab) for ...

Johnson and Johnson’s (J&J) fully subcutaneous Tremfya (guselkumab) has shown a second round of success in ulcerative colitis ...

The FDA has approved Tremfya (guselkumab; Janssen) One-Press, a single-dose patient-controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults. The Food and Drug ...

Johnson & Johnson (J&J) announced new 96-week data from the long-term extensions (LTE) of the phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of Tremfya (guselkumab) in ...

Please provide your email address to receive an email when new articles are posted on . Low body surface area psoriasis in sensitive or highly visible areas is often prescribed only topical ...

Johnson & Johnson (NYSE:JNJ) ranks among the top picks for a retirement portfolio. On September 26, Johnson & Johnson (NYSE:JNJ) reported that the US FDA had approved a subcutaneous induction protocol ...

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension ...